Pharmacotherapy and psychotherapy for body dysmorphic disorder
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Body dysmorphic disorder (BDD) is a prevalent and disabling preoccupation with a slight or imagined defect in appearance. Trials have investigated the use of serotonin reuptake inhibitors (SRIs) and cognitive behaviour therapy (CBT) for BDD. OBJECTIVES: To assess the efficacy of pharmacotherapy, psychotherapy or a combination of both treatment modalities for body dysmorphic disorder. SEARCH STRATEGY: We searched the Cochrane Depression, Anxiety and Neurosis Trial Register (December 2007), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 4, 2007), MEDLINE (January 1966 to December 2007), and PsycINFO (1967 to December 2007). Ongoing and unpublished trials were located through searching the metaRegister of Controlled Trials, the CRISP and WHO ICTRP search portals (databases searched in December 2007), and through contacting key researchers and pharmaceutical companies. Additional studies were located through study reference lists. SELECTION CRITERIA: Randomised controlled trials (RCTs) of patients meeting DSM or ICD diagnostic criteria for BDD, in which the trials compare pharmacotherapy, psychotherapy or multi-modal treatment groups with active or non-active control groups. Short or long-term trials were eligible. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed RCTs for inclusion in the review, collated trial data, and assessed trial quality. Investigators were contacted to obtain missing data. Summary effect sizes for dichotomous and continuous outcomes were calculated using a random effects model and heterogeneity was assessed. MAIN RESULTS: Two pharmacotherapy and three psychotherapy trials were eligible for inclusion in the review, with data from four short-term RCTs (169 participants) available for analysis. Response data from a single placebo-controlled trial of fluoxetine suggested overall superiority of medication relative to placebo (relative risk (RR) 3.07, 95% CI 1.4 to 6.72, n = 67). Symptom severity was also significantly reduced in the RCTs of fluoxetine and clomipramine (relative to desipramine), as well as in the two CBT trials (WMD -44.96, 95% CI -54.43 to -35.49, n = 73). A low relapse rate (4/22) was demonstrated in one trial of CBT. AUTHORS' CONCLUSIONS: Results from the small number of available RCTs suggest that SRIs and CBT may be useful in treating patients with BDD. The findings of these studies need to be replicated. In addition, future controlled studies in other samples, such as adolescents, and using other selective SRIs, as well as a range of psychological therapy approaches and modalities (alone and in combination), are essential in supplementing the sparse data currently available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Baxter, L. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090009002 · Cited by 1,293
Hunter, J. E., & Schmidt, F. L. (2000) · International Journal of Selection and Assessment · doi:10.1111/1468-2389.00156 · Cited by 833
Robinson, K. A., & Dickersin, K. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.150 · Cited by 833
Linear mixed models for longitudinal data
(2000) · Springer Series in Statistics · doi:10.1007/b98969 · Cited by 818
The Brown assessment of beliefs scale: Reliability and validity
Eisen, J. L., Phillips, K. A., Baer, L., Beer, D. A., Atala, K. D., & Rasmussen, S. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.102 · Cited by 705
Deeks, J. J. (2002) · Statistics in Medicine · doi:10.1002/sim.1188 · Cited by 660
Higgins, J. P., Deeks, J. J., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch16 · Cited by 475
Cognitive-behavioral body image therapy for body dysmorphic disorder
Rosen, J. C., Reiter, J., & Orosan, P. (1995) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.63.2.263 · Cited by 384
Surgical and Nonpsychiatric Medical Treatment of Patients With Body Dysmorphic Disorder
Phillips, K. A., Grant, J., Siniscalchi, J., & Albertini, R. S. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.6.504 · Cited by 368
Gender similarities and differences in 200 individuals with body dysmorphic disorder
Phillips, K. A., Menard, W., & Fay, C. (2006) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2005.07.002 · Cited by 242
Development of a quality assessment instrument for trials of treatments for depression and neurosis
Moncrieff, J., Churchill, R., Drummond, D. C., & McGuire, H. (2001) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.108 · Cited by 185
Outcome of cosmetic surgery and ‘DIY’ surgery in patients with body dysmorphic disorder
Veale, D. (2000) · Psychiatric Bulletin · doi:10.1192/pb.24.6.218 · Cited by 154
Tignol, J., Biraben-Gotzamanis, L., Martin-Guehl, C., Grabot, D., & Aouizerate, B. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.05.003 · Cited by 127
Neuropsychological performance in body dysmorphic disorder
Hanes, K. R. (1998) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617798001672 · Cited by 80
Research works printed but not linked: 68
- Hollander, 1999, Clomipramine vs des ipramine crossover trial in body dysmorphic disorder, Archives of General Psychiatry, 56, 1033, 10.1001/archpsyc.56.11.1033 · DOI · Paper page
- McKay, 1999, Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder, Behavior Modification, 23, 620, 10.1177/0145445599234006 · DOI · Paper page
- McKay, 1997, Body dysmorphic disorder: A preliminary evaluation of treatment and maintenance using exposure with response prevention, Behaviour Research and Therapy, 35, 67, 10.1016/S0005-7967(96)00082-4 · DOI
- Phillips, 2004, Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: A placebo-controlled study, Psychosomatics, 45, 438, 10.1176/appi.psy.45.5.438 · DOI
- Phillips, 2002, A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder, Archives of General Psychiatry, 59, 381, 10.1001/archpsyc.59.4.381 · DOI · Paper page
- Veale, 1996, Body dysmorphic disorder: A cognitive behavioural model and pilot randomised controlled trial, Behavioural Research and Therapy, 34, 717, 10.1016/0005-7967(96)00025-3 · DOI · Paper page
- Allen, 2008, An open-label trial of venlafaxine in body dysmorphic disorder, CNS Spectr ums, 13, 138, 10.1017/S1092852900016291 · DOI
- Campisi, 1995, Exposure and response prevention in the treatment of body dysmorphic disorder, Dissertations Abstracts International: Section B: The Sciences and Engineering, 56, 7036
- Geremia, 2001, Cognitive therapy in the treatment of body dysmorphic disorder, Clinical Psychology and Psychotherapy, 8, 243, 10.1002/cpp.284 · DOI
- Gomez-Perez, 1994, Dysmorphobia: Clinical features and outcome with behaviour therapy, European Psychiatry, 9, 229, 10.1017/S0924933800003564 · DOI
- Khemlani-Patel, 2001, Cognitive and behaviour therapy for body dysmorphic disorder: A comparative investigation, Dissertation Abstracts International: Section B: The Sciences and Engineering, 62, 1087
- Neziroglu, 1993, Body dysmorphic disorder: phenomenology and case descriptions, Behavioural Psychotherapy, 21, 27, 10.1017/S0141347300017778 · DOI · Paper page
- Neziroglu, 1996, Effects of cognitive behavior therapy on persons with body dysmorphic disorder and comorbid axis II diagnoses, Behavior Therapy, 27, 67, 10.1016/S0005-7894(96)80036-0 · DOI
- Perugi, 1996, Fluvoxamine in the treatment of body dysmorphic disorder, International Clinical Psychopharmacology, 11, 274, 10.1097/00004850-199612000-00006 · DOI · Paper page
- Phillips, 1996, An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder, Psychopharmacology Bulletin, 32, 175
- Phillips, 1998, Efficacy and safety of fluvoxamine in body dysmorphic disorder, Journal of Clinical Psychiatry, 59, 165, 10.4088/JCP.v59n0404 · DOI · Paper page
- Phillips, 2001, Delusionality and response in open-label fluvoxamine in body dysmorphic disorder, Journal of Clinical Psychiatry, 62, 87, 10.4088/JCP.v62n0203 · DOI · Paper page
- Phillips, 2003, An open-label study of citalopram in body dysmorphic disorder, Journal of Clinical Psychiatry, 64, 715, 10.4088/JCP.v64n0615 · DOI · Paper page
- Phillips, 2005, Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder, American Journal of Psychiatry, 162, 377, 10.1176/appi.ajp.162.2.377 · DOI · Paper page
- Phillips, 2005, Olanzapine augmentation of fluoxetine in body dysmorphic disorder, American Journal of Psychiatry, 162, 1022, 10.1176/appi.ajp.162.5.1022-a · DOI
- Phillips, 2006, An open-label study of escitalopram in body dysmorphic disorder, International Clinical Psychopharmacology, 21, 177, 10.1097/01.yic.0000194378.65460.ef · DOI · Paper page
- Wilhelm, 1999, Cognitive behavior group therapy for body dysmorphic disorder: a case series, Behaviour Research and Therapy, 37, 71, 10.1016/S0005-7967(98)00109-0 · DOI
- American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders
- American Psychiatric Association, 1994, Diagnostic and statistical manual of mental disorders
- Beck, 1987, Beck Depression Inventory: Manual
- Bohne, 2002, Prevalence of body dysmorphic disorder in a German college student sample, Psychiatry Res earch, 109, 101, 10.1016/S0165-1781(01)00363-8 · DOI · Paper page
- Bohne, 2002, Prevalence of symptoms of body dysmorphic disorder and its correlates: a cross-cultural comparison, Psychosomatics, 43, 486, 10.1176/appi.psy.43.6.486 · DOI · Paper page
- Deckersbach, 2000, Characteristics of memory dysfunction in body dysmorphic disorder, Journal of the International Neuropsychological Society, 6, 673, 10.1017/S1355617700666055 · DOI · Paper page
- Deeks, 2008, Analysing and presenting results
- Eisen, 2004, Insight in obsessive compulsive disorder and body dysmorphic disorder, Comprehensive Psychiatry, 45, 10, 10.1016/j.comppsych.2003.09.010 · DOI · Paper page
- Faravelli, 1997, Epidemiology of somatoform disorders: A community survey in Florence, Social Psychiatry and Psychiatric Epidemiology, 32, 24, 10.1007/BF00800664 · DOI · Paper page
- Feusner, 2007, Visual information processing of faces in body dysmorphic disorder, Archives of General Psychiatry, 64, 1417, 10.1001/archpsyc.64.12.1417 · DOI · Paper page
- Foa, 1995, DSM-IV field trial: obsessive-compulsive disorder, American Journal of Psychiatry, 152, 90
- Frare, 2004, Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features, European Psychiatry, 19, 292, 10.1016/j.eurpsy.2004.04.014 · DOI · Paper page
- Gabbay, 2003, New onset of body dysmorphic disorder following frontotemporal lesion, Neurology, 61, 123, 10.1212/01.WNL.0000069607.30528.D5 · DOI
- Gury, 1999, Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability, Encephale, 25, 470
- Guy, 1976, ECDEU assessment manual for psychopharmacology
- Higgins, 2003, Measuring inconsistency in meta-analyses, British Medical Journal, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Hollander, 1989, Treatment of body-dysmorphic disorder with serotonin reuptake blockers, American Journal of Psychiatry, 146, 768, 10.1176/ajp.146.6.768 · DOI · Paper page
- Hollander, 1993, Body image and experience disorders: Body dysmorphic and depersonalization disorders, 17
- JC Ipser, 2006, Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders, Cochrane Database of Systematic Reviews
- Leon, 1999, The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment, Psychological Medicine, 29, 869, 10.1017/S0033291799008570 · DOI · Paper page
- Marks, 1988, Dysmorphophobic avoidance with disturbed bodily perception: A pilot study of exposure therapy, British Journal of Psychiatry, 152, 674, 10.1192/bjp.152.5.674 · DOI · Paper page
- McKay, 1999, Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder, Behavior Modification, 23, 620, 10.1177/0145445599234006 · DOI · Paper page
- Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- National Institute for Clinical Excellence, 2005, The management of post traumatic stress disorder in primary and secondary care
- Phillips, 1991, Body dysmorphic disorder: The distress of imagined ugliness, American Journal of Psychiatry, 148, 1138, 10.1176/ajp.148.9.1138 · DOI · Paper page
- Phillips, 1993, Body dysmorphic disorder: 30 cases of imagined ugliness, American Journal of Psychiatry, 150, 302, 10.1176/ajp.150.2.302 · DOI · Paper page
- Phillips, 1994, A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases, Psychopharmacology Bulletin, 30, 179
- Phillips, 1997, Gender differences in body dysmorphic disorder, Journal of Nervous and Mental Disease, 185, 570, 10.1097/00005053-199709000-00006 · DOI · Paper page
- Phillips, 1997, A severity rating scale for body dysmorphic disorder: Development, reliability and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale, Psychopharmacology Bulletin, 33, 17
- Phillips, 2000, Rate of body dysmorphic disorder in dermatology patients, Journal of the American Academy of Dermatology, 42, 436, 10.1016/S0190-9622(00)90215-9 · DOI · Paper page
- Phillips, 2001, Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study, Journal of Clinical Psychiatry, 62, 721, 10.4088/JCP.v62n0910 · DOI · Paper page
- Phillips, 2004, Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: A place-controlled study, Psychosomatics, 45, 438, 10.1176/appi.psy.45.5.438 · DOI
- Phillips, 2006, Delusional versus nondelusional body dysmorphic disorder: Clinical features and course of illness, Journal of Psychiatric Research, 40, 95, 10.1016/j.jpsychires.2005.08.005 · DOI
- Phillips, 2006, Associations in the longitudinal course of body dysmorphic disorder with major depression, obsessive-compulsive disorder, and social phobia, Journal of Psychiatric Research, 40, 360, 10.1016/j.jpsychires.2005.10.001 · DOI
- Phillips, 2006, Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness, Journal of Psychiatric Resear ch, 40, 95, 10.1016/j.jpsychires.2005.08.005 · DOI
- Rauch, 2003, A preliminary morphometric magnetic resonance imaging study of regional brain volumes in body dysmorphic disorder, Psychiatry Research, 122, 13, 10.1016/S0925-4927(02)00117-8 · DOI
- Rosen, 1996, Development of the Body Dysmorphic Disorder Examination, Behaviour Research and Therapy, 34, 755, 10.1016/0005-7967(96)00024-1 · DOI · Paper page
- Rosen, 1998, A comparison of eating disorders and body dysmorphic disorders on body image and psychological adjustment, Journal of Psychosomatic Research, 44, 441, 10.1016/S0022-3999(97)00269-9 · DOI · Paper page
- Saxena, 2001, A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder, Journal of Clinical Psychiatry, 62, 67, 10.4088/JCP.v62n0114b · DOI
- Schneier, 1994, Functional impairment in social phobia, J ournal of Clin ical Psychiatry, 55, 322
- Spitzer, 1996, Instructional manual for the structured clinical interview for DSM-IV.
- Veale, 1996, Body dysmorphic disorder: A survey of fifty cases, British Journal of Psychiatry, 169, 196, 10.1192/bjp.169.2.196 · DOI · Paper page
- Ware, 1993, SF-36 Health Survey Manual and Interpretation Guide
- World Health Organisation, 1975, The ICD-9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
- World Health Organisation, 1992, ICD-10 International statistical classification of diseases and related health problems : based on the International Statistical Classification of Diseases and Related Health Problems, ICD
- Williams, 2006, A meta-analysis of psychological and pharmacological treatments for Body Dysmorphic Disorder, Beha viour Research and Therapy, 44, 99, 10.1016/j.brat.2004.12.006 · DOI · Paper page
Cited by
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?
Phillips, K. A., Stein, D. J., Rauch, S. L., Hollander, E., Fallon, B. A., Barsky, A., Fineberg, N., Mataix-Cols, D., Ferrão, Y. A., Saxena, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20705 · Cited by 347
Self-citationvan Dessel, N., den Boeft, M., van der Wouden, J. C., Kleinstäuber, M., Leone, S. S., Terluin, B., Numans, M. E., van der Horst, H. E., & van Marwijk, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011142.pub2 · Cited by 302
Metadata
- Authors
- Ipser, J. C., Sander, C., & Stein, D. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2009-01-21
- Issue
- 1
- Pages
- CD005332-CD005332
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2138759993
- Cited by
- 152
- References
- 21
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.